https://www.prnewswire.com/news-releases/rg-125-azd4076-a-microrna-therapeutic-targeting-microrna-103107-for-the-treatment-of-nash-in-patients-with-type-2-diabetespre-diabetes-selected-as-clinical-candidate-by-astrazeneca-300062261.html
RG-125 (AZD4076), a microRNA Therapeutic Targeting microRNA-103/107 for the Treatment of NASH in...
/PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ:RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting...